Mr McIntyre has more than 20 years of executive experience in the life sciences sector, having held various C-suite level roles at Anthos Therapeutics, Inc., Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. Mr McIntyres experience also includes seven years as a Partner at Apple Tree Partners. During this time, Mr McIntyre served as a non-executive director of several US life science companies. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker McKenzie and KPMG in M&A, initial public offerings, and corporate law and also held various senior finance roles in both multinational companies and small growth companies. Mr McIntyre is based in the US and brings an international lens on life science development, licensing and commercialisation, marketing, business development, and M&A/capital markets. Mr McIntyre has experience in the areas of accounting, corporate finance, audit, risk management, organisational strategy, drug development, regulatory and corporate affairs. Mr McIntyre is the Chief Financial Officer of clinical-stage pharmaceutical company, Inhibikase Therapeutics Inc (NASDAQ: IKT). He also Chair the Risk Committee.
